Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1351

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 5
Chunk 1351
---
 Allen has
extensive experience in business strategy and structuring and executing a variety of investment banking and capital markets transactions,
including financings, initial public offerings, and mergers and acquisitions. Prior to his work in the blockchain industry at BTCS, he
worked domestically and internationally on projects in technology, media, natural resources, logistics, medical services, and financial
services. He has served as a managing director at numerous boutique investment banks focused on advising and raising capital for small
and mid-size companies. Mr. Allen received a Bachelor of Science in Mechanical Engineering from Lehigh University and a Master of Business
Administration from the Mason School of Business at the College of William & Mary. The Board concluded that Mr. Allen’s background
and leadership experiences in the financial industry qualify him to be a member of the Board.

Cheryl Xu is one of our directors
since July 11, 2023 and until recently served as Biogen’s Vice President, Public Policy & Government Affairs since 2020. Ms.
Xu was PhRMA’s first Representative to China. Subsequently she started a consulting business in 2005, advising well-known multinational
companies such as Pfizer, J&J and UnitedHealth Group on their market access and expansion strategies in China. Cheryl has provided
consultations to both the U.S. and Chinese governments on pharmaceutical policies including strengthening of IP protection and monitoring
system for China’s API exports. Prior to that, she was the Director of International Finance at Pharmacia based in New Jersey from
1998 to 2003. Ms. Xu received her Bachelor of Science degree in Physics from Peking University, and Master of Business Administration
in Finance from Washington University in St. Louis. The Board concluded that Ms. Xu’s background and leadership experiences in
the pharmaceutical industry qualify her to be a member of the Board.

Dr. Stephen Toovey is one of our
directors since July 11, 2023 and is an infectious and tropical disease physician. Dr. Toovey has worked in the pharmaceutical industry
and academia in both developed and developing countries, and currently specializes in the research of influenza and other respiratory
viruses, malaria, rabies and the neurological aspects of infectious diseases. He is currently the Chief Executive Officer of Pegasus,
a medical and scientific services company and has held that position since 2008. Dr. Toovey also advises a number of pharmaceutical companies
and biotech organizations on infection and immunology related matters, from translation through Phase IV, and